Distal-less homeobox 5 (DLX5)

Distal-less homeobox 5 (DLX5) is a transcription factor belonging to the homeobox gene family, closely related to the Drosophila distal-less gene[1][2][3]. DLX5 plays essential roles in embryogenesis, particularly in craniofacial and limb patterning, bone and skeletal development, fracture healing, and inner ear morphogenesis[1][3]. DLX5 functions by regulating osteoblast-specific genes and integrates into signaling pathways such as bone morphogenetic proteins (BMPs). Mutations or dysregulation of DLX5 are associated with congenital limb malformations, most notably split hand/foot malformation type 1 (SHFM1), as well as craniofacial abnormalities and sensorineural hearing loss[1][2][3]. DLX5 is also implicated in oncogenesis, promoting cell proliferation in various cancers (e.g., lung, breast, ovarian, lymphoma) by transactivating oncogenes such as MYC[2][3]. Structural studies show that DLX5 binds DNA via a helix-turn-helix homeodomain motif and that pathogenic mutations reduce DNA-binding affinity, contributing to developmental abnormalities[2]. At this time, DLX5 is not a direct therapeutic target, and no drugs are currently approved to modulate its activity in clinical settings.

Other names

Homeobox protein DLX-5SHFM1SHFM1DDistal-less homeo box 5Split hand/foot malformation type 1 with sensorineural hearing loss

Not applicable (no directly approved drugs or small molecules that specifically target DLX5 as a therapeutic target have been described in current literature)